Form 4: Adverum COO Buys 50,000 Shares in Planned Transaction

Adverum Biotechnologies' Chief Operating Officer, Peter Soparkar, acquired 50,000 shares of common stock at a weighted-average price of $4.22 per share.

Summary

• Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, Inc. (ADVM), purchased 50,000 shares of common stock.
• The transaction occurred on December 5, 2025.
• The shares were acquired at a weighted-average price of $4.22 per share, with individual purchase prices ranging from $4.18 to $4.24.
• Following this transaction, Soparkar beneficially owns a total of 80,189 shares of Adverum Biotechnologies common stock.
• The purchase was made pursuant to a Rule 10b5-1 pre-planned trading arrangement.
• The total beneficial ownership includes 1,200 shares acquired earlier in 2025 through the company's 2014 Employee Stock Purchase Plan (600 shares on May 21, 2025, and 600 shares on November 20, 2025).

Sentiment

Score: 7

Explanation: An insider purchase by a high-ranking officer generally indicates positive sentiment and confidence in the company's future performance, especially when executed under a Rule 10b5-1 plan.

Positives

• Chief Operating Officer Peter Soparkar's purchase of 50,000 shares demonstrates insider confidence in Adverum Biotechnologies, Inc.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than opportunistic trading.

Future Outlook

The filing does not provide specific forward-looking statements or guidance, as it is a report of an insider transaction.

Industry Context

Insider purchases, especially by high-ranking officers like a Chief Operating Officer, can signal management's belief in the company's future prospects within the biotechnology sector. This transaction occurs in an industry often characterized by high R&D costs and significant potential for drug development success.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of management confidence, potentially influencing investor sentiment.
• Employees: May see the COO's investment as a sign of commitment to the company's long-term success.

Key Dates

Recommendation

The purchase of 50,000 shares by the Chief Operating Officer, Peter Soparkar, at a weighted-average price of $4.22 per share, signals insider confidence in Adverum Biotechnologies. This transaction, executed under a Rule 10b5-1 plan, suggests a pre-meditated belief in the company's value. While insider buying is generally a positive indicator, a single Form 4 filing does not provide sufficient comprehensive financial or strategic information to warrant a 'buy' or 'strong buy' recommendation without further analysis of the company's fundamentals, industry position, and future prospects. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal while awaiting more detailed financial disclosures.

Keywords

Adverum Biotechnologies, ADVM, Insider Trading, Stock Purchase, Peter Soparkar, COO, Form 4, Equity Acquisition, Biotechnology